Back to Journals » Clinical Ophthalmology » Volume 7
Adjuvant corneal crosslinking to prevent hyperopic LASIK regression
Authors Aslanides IM , Mukherjee AN
Received 31 October 2012
Accepted for publication 20 December 2012
Published 31 March 2013 Volume 2013:7 Pages 637—641
DOI https://doi.org/10.2147/OPTH.S39796
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Ioannis M Aslanides, Achyut N Mukherjee
Emmetropia Mediterranean Eye Clinic, Heraklion, Crete, Greece
Purpose: To report the long term outcomes, safety, stability, and efficacy in a pilot series of simultaneous hyperopic laser assisted in situ keratomileusis (LASIK) and corneal crosslinking (CXL).
Method: A small cohort series of five eyes, with clinically suboptimal topography and/or thickness, underwent LASIK surgery with immediate riboflavin application under the flap, followed by UV light irradiation. Postoperative assessment was performed at 1, 3, 6, and 12 months, with late follow up at 4 years, and results were compared with a matched cohort that received LASIK only.
Results: The average age of the LASIK-CXL group was 39 years (26–46), and the average spherical equivalent hyperopic refractive error was +3.45 diopters (standard deviation 0.76; range 2.5 to 4.5). All eyes maintained refractive stability over the 4 years. There were no complications related to CXL, and topographic and clinical outcomes were as expected for standard LASIK.
Conclusion: This limited series suggests that simultaneous LASIK and CXL for hyperopia is safe. Outcomes of the small cohort suggest that this technique may be promising for ameliorating hyperopic regression, presumed to be biomechanical in origin, and may also address ectasia risk.
Keyword: CXL
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.